

Advisory Committees

National Advisory Committee

Juan Ignacio Arcelus Martínez (Granada, Spain)
Juan F. Ascaso (Valencia, Spain)
José Antonio Aznar (Valencia, Spain)
Javier Batlle Fonrodona (A Coruña, Spain)
Isabel Díaz-Ricart (Barcelona, Spain)
Pere Domenech Santasusana (Barcelona, Spain)
Ginés Escolar Albadalejo (Barcelona, Spain)
Antonio Fernández-Ortiz (Madrid, Spain)
Jordi Fontcuberta Boj (Barcelona, Spain)
Pablo García de Frutos (Barcelona, Spain)
David García-Dorado (Barcelona, Spain)
Luís Javier García Frade (Valladolid, Spain)
José Ramón González-Juanatey (Santiago de compostela, Spain)

Magda Heras (Barcelona, Spain)
José Hermida (Pamplona, Spain)
David Jiménez Castro (Madrid, Spain)
Ramón Lecumberri Villamediana (Pamplona, Spain)
María Fernanda López Fernández (A Coruña, Spain)
Pascual Marco Vera (Alicante, Spain)
Constantino Martínez Martínez (Murcia, Spain)
Manuel Monreal Bosch (Barcelona, Spain)
Joan Montaner Villalonga (Barcelona, Spain)
José Antonio Páramo Fernández (Pamplona, Spain)
Juan Carlos Reverter Calatayud (Barcelona, Spain)
Miguel Ángel Sanz Alonso (Valencia, Spain)
Francisco Velasco Jimeno (Córdoba, Spain)

International Advisory Committee

Raul Altman (Argentina)
Juan José Badimon (USA)
Alicia Blanco (Argentina)
Henri Bounameaux (Switzerland)
Benjamin Brenner (Israel)
Harry R. Büller (The Netherlands)
Marco Cattaneo (Italy)
Sergio Coccheri (Italy)
Ola E. Dahl (Norway)
Bjorn Dahlback (Sweden)
Raffaele de Caterina (Italy)
Ismail Elalamy (France)
Charles T. Esmon (USA)
Anna Falanga (Italy)
Valentín Fuster (USA)

John Griffin (USA)
Kurt Huber (Austria)
Gerhard Johnson (USA)
Nevine Kassim (Egypt)
Gili Kenet (Israel)
David A. Lane (United Kingdom)
Marcel Levi (The Netherlands)
Christos Liapis (Greece)
Gregory YH Lip (United Kingdom)
Pier Mannucci (Italy)
Diego Mezzano (Chile)
Joao Morais (Portugal)
Pierre-Emmanuel Morange (France)
Ulrike Nowak Göttl (Germany)

Paolo Prandoni (Italy)
P H Reitsma (The Netherlands)
Bianca Rocca (Italy)
Meyer Michel Samama (France)
Per Morten Sandset (Sweden)
Jean-François Schved (France)
Uri Seligsohn (Israel)
Paolo Simioni (Italy)
Mojca Stegnar (Slovenia)
Svetlana M Strukova (Russia)
Ali Taher (Lebanon)
Turgut Ulutin (Turkey)
David Varon (Israel)
Denisa Wagner (USA)
Steve Watson (United Kingdom)

Committees

Congress Executive Committee

President
Lina Badimón

Vice-President
M. Teresa Santos

Vice-President
Vicente Vicente

Members
M. Ángeles Dasí
Francisco España
Amparo Estellés
Juana Vallés
Virtudes Vila

Local Organizing Committee

Maria Borrell
Aitana Braza
Javier Corral
Pilar Medina
Antonio Moscardó
Teresa Padró
Jose Rivera
Vanesa Roldán
Gemma Vilahur

Organized By



THE MEDITERRANEAN LEAGUE
AGAINST THROMBOEMBOLIC DISEASES
www.medleague-thrombosis.org



TECHNICAL SECRETARIAT
Phone: +34 963 524 889 - Fax: +34 963 942 558
e-mail: thrombosis@geyseco.es



THE MEDITERRANEAN LEAGUE
AGAINST THROMBOEMBOLIC DISEASES
www.medleague-thrombosis.org

**23rd
Biannual
International
Congress on
Thrombosis**
14-17 MAY 2014

VALENCIA-SPAIN
CONVENTION CENTER

www.thrombosis2014.org

Preliminary Programme

23rd Biannual International Congress on Thrombosis

14-17 MAY 2014

EDUCATIONAL SYMPOSIUM UPDATE ON THROMBOSIS 2014

1. Antiphospholipid syndrome: From pathogenesis to novel immunomodulatory therapies.
2. Laboratory monitoring of coagulation. Problems and solutions.
3. Bleeding management of patients under antithrombotic therapy.
4. Heparins in the 21st century.

STATES-OF-THE-ART HEMOSTASIS AND THROMBOSIS: CHALLENGE OF THE FUTURE

1. Building bridges between different elements of the hemostatic system and beyond.
2. Arterial thrombosis - Cardiovascular Disease – Global Epidemics.

BLOCKING THROMBOSIS IN INTERVENTIONAL PROCEDURES: THE KEY TO SUCCESS

1. Reducing the burden of thrombosis in interventional cardiology.
2. Thromboembolism in surgery.

POSTGENOMICS APPROACHES IN THROMBOSIS

1. Proteomics in thrombosis: Current perspective.
2. mRNAs in thrombosis and haemostasis.

SYMPOSIUMS

1. JOINT SYMPOSIUM

Sociedad Española de Trombosis y Hemostasia (SETH)
Società Italiana per lo studio dell'Emostasi e della Trombosi (SISET)
Mediterranean League Against Thromboembolic Diseases (MLTD)

1. Unravelling novel thromboembolic mechanisms.
2. Blockade of the VWF-GPIb interaction in arterial thrombosis: where are we ?.
3. What did we learn from RIETE?.
4. RNA-based therapeutic approaches to coagulation defects.

2. THROMBOSIS AND CANCER

1. Coagulation and cancer: biological and clinical aspects.
2. New and old anticoagulants in cancer.
3. Thrombosis related angiogenesis and metastasis.

3. THROMBOSIS IN CHILDREN

1. Inherited thrombophilia in children. What's new?.
2. Thrombosis & Brain. Management of venous and arterial thrombosis in children.
3. Thrombosis & Heart. News in pediatric anticoagulation and antiaggregation.

4. TREATMENT OF THROMBOSIS IN CORONARY ARTERY DISEASE IN 2014

1. Update in anti-P2Y12 drugs in coronary artery disease.
2. Update in anticoagulants in coronary artery disease.
3. Global Management of acute coronary syndrome.

5. GENETICS IN THROMBOSIS

1. Mouse models and genomic search for new genes involved in platelet reactivity or count.
2. Genome-wide association studies in thrombosis.
3. New approaches to identify genetic risk factors in thrombosis.

6. ADVANCES IN UNDERSTANDING PLATELET FUNCTION: MOLECULAR APPROACHES

1. GPVI signaling in platelet function: clinical and pharmacological implications.
2. Mechanisms involved in the platelet procoagulant activity.
3. Understanding endoplasmic reticulum proteins in platelet function.

7. ATRIAL FIBRILLATION: NEW ADVANCES IN DIAGNOSIS AND TREATMENT

1. Beyond risk stratification in AF patients.
2. Treatment options in AF: old vs new drugs.
3. Translating the results from clinical trials to real life.

8. HEMOSTASIS AND THROMBOSIS IN WOMEN

1. Thrombosis, thrombophilia, vascular complications and antithrombotic therapy in pregnancy.
2. Antithrombotic prophylaxis and Assisted reproduction techniques.
3. Fibrinolysis and angiogenesis in gynaecological pathology.

9. NEW INSIGHTS IN PROTEIN C PATHWAY

1. Protein C anticoagulant and cytoprotective pathways.
2. Endothelial protein C receptor and thrombomodulin in venous and arterial thrombosis.
3. Endothelial protein C receptor encryption by sPLA2-V: role in thrombosis and cellular protein C resistance.

10. TREATMENT OF VENOUS THROMBOEMBOLISM

1. Optimal duration of treatment of venous thrombosis.
2. Optimal duration of prophylaxis of postoperative venous thrombosis.
3. Role of the new drugs for maintaining anticoagulant therapy.

11. IMPLICATIONS OF THROMBOSIS IN THE EVOLUTION OF VASCULAR DISEASE

1. Role of tissue factor in endothelial and vascular smooth muscle cell function.
2. The role of platelets in vascular integrity in the context of inflammation.
3. Thrombosis as an intravascular effector of innate immunity.

12. CROSSTALK-MECHANISMS BY MICROPARTICLES IN THROMBOSIS

1. Circulating microparticles.
2. Platelet/monocyte microparticles in cell to cell communication.
3. The role of platelets and their microparticles in rehabilitation of ischemic brain tissue.

13. INFLAMMATION AND THROMBOSIS

1. Oxidative stress and inflammation in thrombosis.
2. Procoagulant activity of circulating nucleic acids and of neutrophil extracellular traps.
3. Innate immunity, inflammation and thrombosis.

14. PRESIDENTIAL FAREWELL SYMPOSIUM NEW CHALLENGES IN THROMBOSIS AND CARDIOVASCULAR DISEASE

December 3, 2013
Deadline Abstracts Submission

more information at: www.thrombosis2014.org

